1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Secondary (Hypogonadotropic) Hypogonadism - Drugs In Development, 2022, provides an overview of the Secondary (Hypogonadotropic) Hypogonadism (Male Health) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Hypogonadotropic hypogonadism (HH) is a form of hypogonadism that is due to a problem with the pituitary gland or hypothalamus. HH is caused by a lack of hormones that normally stimulate the ovaries or testes like gonadotropin-releasing hormone (GnRH), follicle stimulating hormone (FSH) and luteinizing hormone (LH). Symptoms include Lack of development at puberty, enlargement of the testes and penis, deepening of the voice, and facial hair. Treatment includes testosterone, estrogen and progesterone.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Secondary (Hypogonadotropic) Hypogonadism - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Secondary (Hypogonadotropic) Hypogonadism (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Secondary (Hypogonadotropic) Hypogonadism (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Secondary (Hypogonadotropic) Hypogonadism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 2, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.
Secondary (Hypogonadotropic) Hypogonadism (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Secondary (Hypogonadotropic) Hypogonadism (Male Health).
- The pipeline guide reviews pipeline therapeutics for Secondary (Hypogonadotropic) Hypogonadism (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Secondary (Hypogonadotropic) Hypogonadism (Male Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Secondary (Hypogonadotropic) Hypogonadism (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Secondary (Hypogonadotropic) Hypogonadism (Male Health)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Secondary (Hypogonadotropic) Hypogonadism (Male Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Secondary (Hypogonadotropic) Hypogonadism (Male Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Secondary (Hypogonadotropic) Hypogonadism - Overview
- Secondary (Hypogonadotropic) Hypogonadism - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Secondary (Hypogonadotropic) Hypogonadism - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Secondary (Hypogonadotropic) Hypogonadism - Companies Involved in Therapeutics Development
- AbbVie Inc
- Beijing FuKangren Bio-pharm Tech Co Ltd
- Diurnal Group Plc
- IASO BioMed Inc
- Merck & Co Inc
- Mereo Biopharma Group Plc
- Secondary (Hypogonadotropic) Hypogonadism - Drug Profiles
- corifollitropin alfa - Drug Profile
- Product Description
- Mechanism Of Action
- enclomiphene citrate - Drug Profile
- Product Description
- Mechanism Of Action
- IAS-167A - Drug Profile
- Product Description
- Mechanism Of Action
- Kisspeptin-10 - Drug Profile
- Product Description
- Mechanism Of Action
- leflutrozole - Drug Profile
- Product Description
- Mechanism Of Action
- Rifene - Drug Profile
- Product Description
- Mechanism Of Action
- testosterone - Drug Profile
- Product Description
- Mechanism Of Action
- Secondary (Hypogonadotropic) Hypogonadism - Dormant Projects
- Secondary (Hypogonadotropic) Hypogonadism - Discontinued Products
- Secondary (Hypogonadotropic) Hypogonadism - Product Development Milestones
- Featured News & Press Releases
- Oct 11, 2021: Phase 1 data for DITEST published in European Journal of Endocrinology
- Jul 30, 2020: Diurnal Group announces positive DITEST regulatory meeting with US FDA
- Jan 15, 2019: Mereo BioPharma: BGS-649 Phase 2b data to be Presented at ENDO 2019
- Dec 17, 2018: Mereo BioPharma announces positive results from the safety extension study to the phase 2b clinical trial of BGS-649 for the treatment of hypogonadotropic hypogonadism in obese men
- Sep 05, 2017: Completion of Patient Enrolment in Phase 2b dose-confirmation study of BGS-649 for the treatment of hypogonadotropic hypogonadism
- Mar 07, 2017: Mereo BioPharma Group: Positive recommendation for BGS-649 Phase 2b trial following planned IDMC interim analysis
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Secondary (Hypogonadotropic) Hypogonadism, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Secondary (Hypogonadotropic) Hypogonadism - Pipeline by AbbVie Inc, 2022
- Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Beijing FuKangren Bio-pharm Tech Co Ltd, 2022
- Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Diurnal Group Plc, 2022
- Secondary (Hypogonadotropic) Hypogonadism - Pipeline by IASO BioMed Inc, 2022
- Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Merck & Co Inc, 2022
- Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Mereo Biopharma Group Plc, 2022
- Secondary (Hypogonadotropic) Hypogonadism - Dormant Projects, 2022
- Secondary (Hypogonadotropic) Hypogonadism - Discontinued Products, 2022
- Number of Products under Development for Secondary (Hypogonadotropic) Hypogonadism, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc
- Beijing FuKangren Bio-pharm Tech Co Ltd
- Diurnal Group Plc
- IASO BioMed Inc
- Merck & Co Inc
- Mereo Biopharma Group Plc
